THE USAGE OF CYTOLOGICAL MATERIAL FOR DIAGNOSTICS OF LUNG CANCER
https://doi.org/10.18027//2224-5057-2017-7-4-13-20
Abstract
The article shows the possibilities of the usage of cytological material for diagnostics of lung cancer at the example of work of an oncological outpatient clinic during one year. Light microscopy was used to study of cytological specimens of various material of 721 patients. The method has allowed to determine the diagnosis of lung cancer in majority of the observed cases with definition of histological type in 89%. When comparing the results of cytology with the final diagnosis the difference of determination of the tumor histological types is less than 1%. The immunocytochemical test is used at the examination of pleural fluid of 40 patients without determined primary locus. The immunocytochemical research has allowed specifying the inhering of the tumor cells to the metastasis from the lung, elevating the precision of the diagnostics to 96%. The cytological material of 62 patients obtained during the bronchoscopic examination, puncture of lymphatic nodules, pleural fluid and sputum with presence of a sufficient quantity of tumor cells (not less than 200) represents appropriate material for molecular-genetic research. The usage of cytological material for search of somatic mutations is justified for oncological patients with locally advanced or disseminated process, whose cytological material is the unique accessible morphological material for research.
About the Authors
O. G. Grigoruk
Altai branch of N. N. Blokhin Russian Cancer Research Center; Altai Regional Oncology Center; Altai State Medical University.
Russian Federation
Russian Federation
Olga G. Grigoruk - MD, DSc, Senior Researcher AB of N.N. Blokhin RCRC; Head of the Department of Clinical Laboratory Diagnostics (for carrying out cytological methods of research) AROC; Associate Professor of the Department of General and Biochemical Chemistry, Clinical Laboratory Diagnostics AS MU.
Barnaul
E. I. Pupkova
Altai Regional Oncology Center.
Russian Federation
Russian Federation
Elena I. Pupkova - MD, Head of the Department of Clinical Laboratory Diagnostics (Laboratory of Molecular Diagnostics).
BarnaulL. M. Bazulina
Altai Regional Oncology Center.
Russian Federation
Russian Federation
Larisa M. Bazulina - MD, Department of Clinical Laboratory Diagnostics (for carrying out cytological methods of research).
BarnaulA. F. Lazarev
Altai branch of N. N. Blokhin Russian Cancer Research Center; Altai Regional Oncology Center; Altai State Medical University
Russian Federation
Russian Federation
Alersandr F. Lazarev - MD, DSc Med, Professor, Director of AB of N.N. Blokhin RCRC; Chief Physician AROC; Head of the Department of Oncology and Radiation Therapy and Radiation Diagnostics ASMU.
Barnaul
References
1. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K., Yatabe Y., Ishikawa Y. et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, Arch. Pathol. Lab. Med., 2013 May, Vol. 137 (5), pp. 668–684, doi: 10.5858/arpa.2012-0263-RA.
2. World Health Organization. Histological Typing of Lung Tumors. 2nd ed., World Health Organization, Geneva, Switzerland, 1981.
3. Travis W.D., Colby T.V., Corrin B. et al. Histological Typing of Lung and Pleural Tumors. 3rd ed., Springer, Berlin, Germany, 1999.
4. Righi L., Graziano P., Fornari A. et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fineneedle aspiration cytology: a retrospective study of 103 cases with surgical correlation, Cancer, 2011, Vol. 117 (15), pp. 3416–3423.
5. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart, IARC, Lyon, France, 2004.
6. Raab S.S., Meier F.A., Zarbo R. J. et al. The “Big Dog” effect: variability assessing the causes of error in diagnoses of patients with lung cancer, J. Clin. Oncol., 2006, Vol. 24 (18), pp. 2808–2814.
7. Proietti A., Boldrini L., Ali G., Servadio A., Lupi C., Sensi E., Miccoli M. et al. Histo-cytological diagnostic accuracy in lung cancer. Cytopathology, 2014 Dec, Vol. 25 (6), pp. 404-411, doi: 10.1111/cyt.12117.
8. Rekhtman N., Brandt S.M., Sigel C.S. et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing, J. Thorac. Oncol., 2011, Vol. 6 (3), pp. 451–458.
9. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 2004 Jun 4, Vol. 304 (5676), pp. 1497– 1500.
10. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I. et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc. Natl. Acad. Sci., USA, 2004 Sep 7, Vol. 101 (36), pp. 13306–13311.
11. Mok T.S., Wu Y. L., Thongprasert S., Yang C.H., Chu D. T., Saijo N. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N. Engl. J. Med., 2009 Sep 3, Vol. 361 (10), pp. 947–957, doi: 10.1056/NEJMoa0810699.
12. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E. et al. Spanish Lung Cancer Group in collaboration with Groupe Francais de Pneumo-Cancerologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol., 2012 Mar, Vol. 13 (3), pp. 239–246, doi: 10.1016/S1470–2045(11)70393-X.
13. Sasaki T., Janne P.A. New strategies for treatment of ALK rearranged non-small cell lung cancers, Clin. Cancer Res., 2011, Vol. 17 (23), pp. 7213–7218.
14. Shaw A. T., Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin. Cancer Res., 2011, Vol. 17 (8), pp. 2081–2086.
15. Kwak E. L., Bang Y. J., Camidge D.R. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N. Engl. J. Med., 2010, Vol. 363 (18), pp. 1693–1703.
16. Johnson D.H., Fehrenbacher L., Novotny W. F. et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J. Clin. Oncol., 2004, Vol. 22 (11), pp. 2184–2191.
17. Janne P.A., Meyerson M. ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma, J. Clin. Oncol., 2012, Vol. 30 (8), pp. 878–879.
18. Bergethon K., Shaw A. T., Ou S.H. et al. ROS1 rearrangements define a unique molecular class of lung cancers, J. Clin. Oncol., 2012, Vol. 30 (8), pp. 863–870.
19. Savic S., Tapia C., Grilli B. et al. Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of nonsmall-cell lung cancers, Br. J. Cancer, 2008, Vol. 98 (1), pp. 154–160.
20. Miller V.A., Riely G. J., Zakowski M. F. et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib, J. Clin. Oncol., 2008, Vol. 26 (9), pp. 1472–1478.
21. Nicholson A.G., Gonzalez D., Shah P. et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis, J. Thorac. Oncol., 2010, Vol. 5 (4), pp. 436–441.
22. Григорук О. Г., Лазарев А.Ф., Дударенко С.В., Шойхет Я.Н. Дифференциальная цитологическая диагностика опухолевых и неопухолевых плевральных выпотов. Барнаул: АЗБУКА, 2017. С. 68–84. [Grigoruk O.G., Lazarev A. F., Dudarenko S.V., Shoychet J.N. Differential cytological diagnostics of tumor and non-tumor pleural effusions, Barnaul: AZBUKA, 2017, pp. 68–84. (In Russ.)].
Review
For citations:
Grigoruk O.G., Pupkova E.I., Bazulina L.M., Lazarev A.F. THE USAGE OF CYTOLOGICAL MATERIAL FOR DIAGNOSTICS OF LUNG CANCER. Malignant tumours. 2017;7(4):13-20. (In Russ.) https://doi.org/10.18027//2224-5057-2017-7-4-13-20
Views:
892
Email this article 